Standard
Guardant Health ordered to pay $245M in patent dispute
In a significant legal blow to one of the leaders in the liquid biopsy market, a U.S. federal court has issued a final judgment confirming that Guardant Health willfully infringed upon two foundational patents related to high-accuracy DNA sequencing. The ruling, which follows a multi-year legal battle involving TwinStrand Biosciences and the University of Washington,…
